merck news - Search News

Merck to develop weight loss pill from Chinese drugmaker

Merck signs up to $2 billion deal for oral weight-loss drug with China's Hansoh

U.S. drugmaker Merck on Wednesday signed a deal worth up to $2 billion with Hansoh Pharmaceuticals to develop and commercialize the Chinese biotech's experimental obesity drug.

NBC New York · 2d

Merck to develop weight loss pill from Chinese drugmaker in up to $2 billion licensing deal

Merck will pay Hansoh $112 million upfront for rights to the drug, with the potential for an additional $1.9 billion in payments and royalties on sales.

YAHOO!Finance · 2d

Merck moves into obesity with deal for Hansoh’s GLP-1 pill

News of Merck’s licensing of Hansoh’s preclinical medicine pressured shares in Viking and other obesity drug developers seen as likely buyout targets.

HIV, Merck

Hosted on MSN · 1d

Merck's HIV treatment meets main goal in two late-stage studies

Merck's experimental two-drug combination met the main goal of significantly suppressing replication of the HIV-1 virus in adults receiving another form of therapy in two late-stage studies, the company said on Thursday.

YAHOO!Finance · 1d

Merck's Investigational Two-Drug Regime For HIV Meets Primary Goal In Two Late-Stage Trials

Merck & Co Inc (NYSE:MRK) revealed topline results from two pivotal Phase 3 trials of a two-drug regimen of doravirine/islatravir (DOR/ISL) in adults with HIV-1 infection. The trials included patients who were virologically suppressed on different antiretroviral therapy regimens,

Seeking Alpha on MSN · 1d

Merck posts mixed late-stage trial results for HIV treatment

Merck (MRK) stock in focus as company reports mixed results in Phase 3 trials for HIV therapy islatravir in combination with doravirine. Read more here.

6hon MSN

Merck-AstraZeneca breast cancer drug reduces risk of death by 28% in patients diagnosed early, clinical trial shows

About 87.5% of patients treated with the drug were alive after six years, compared to 83.2% who received a placebo.

FiercePharma16h

Mirroring Merck's problem, GSK's Jemperli-Zejula study in ovarian cancer misses survival goal

Perhaps PD-1 inhibitors just aren’t for ovarian cancer after all. | Merck's and GSK's similar overall survival setbacks ...

Merck & Co. Inc. stock underperforms Friday when compared to competitors

Merck & Co. Inc. closed $36.58 short of its 52-week high ($134.63), which the company achieved on June 25th.

19h

Merck closes exclusive global license agreement for LM-299 from LaNova Medicines

Merck (MRK) announced the closing of the exclusive global license agreement for LM-299, a novel investigational PD-1/VEGF bispecific antibody, ...

Merck discontinues development of 2 experimental cancer drugs after trial failures

Merck said on Monday it has discontinued the development of two experimental cancer drugs after their failure in several ...

12hon MSN

Stocks on the Move: Uber, Carmax, Novo Nordisk, Eli Lilly, Merck, Crown Castle and Accenture

I Asked 3 Food Experts To Name the Best Peanut Butter—They All Said the Same Brand ...

13h

Strategic Moves in Cardiometabolic Space: Merck’s Buy Rating for Innovative Combination Therapies

Jefferies analyst Akash Tewari has maintained their bullish stance on MRK stock, giving a Buy rating on December 18.Pick the best stocks and ...

bovnews16h

Merck & Co Inc (MRK) Stock: More Strategic Than Meets the Eye

Merck & Co Inc (MRK) stock saw a modest uptick, ending the day at $99.52 which represents a slight increase of $1.18 or 1.20% from the prior close of $98.34. The stock opened at $98.56 and touched a ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Merck to develop weight loss pill from Chinese drugmaker

HIV, Merck

Related topics